Incyte Strengthens Leadership Team with Key Senior Appointments to Drive Long-Term Growth
Incyte has announced a series of strategic appointments to its senior management team, reinforcing its leadership structure as the company continues to advance its long-term growth strategy and innovation pipeline. These leadership changes highlight Incyte’s commitment to strengthening its research, clinical development, and commercial operations as it expands its global footprint in biopharmaceutical innovation.
The newly announced appointments recognize the significant contributions of three experienced leaders within the organization—Dr. Pablo J. Cagnoni, Dr. Steven Stein, and Mohamed Issa—each of whom will take on expanded roles designed to align with Incyte’s evolving priorities in research, development, and commercialization.
Expanded Leadership in Research and Development
Dr. Pablo J. Cagnoni has been appointed President of Incyte in addition to his role as Global Head of Research and Development. In this expanded capacity, Dr. Cagnoni will continue to oversee the company’s R&D efforts while playing a more prominent role in shaping corporate strategy and ensuring effective execution across the organization.
Under Dr. Cagnoni’s scientific leadership, Incyte has achieved notable advancements in its research and development pipeline. The company has made significant progress in several key programs, including therapies targeting mutCALR antibodies, povorcitinib, CDK2, KRAS G12D, and TGFβR2xPD1. These programs represent critical areas of innovation in oncology and immunology, reflecting Incyte’s focus on addressing complex and unmet medical needs.
In addition to advancing the pipeline, Dr. Cagnoni has been instrumental in modernizing Incyte’s R&D infrastructure. He has introduced new organizational structures, streamlined processes, and implemented advanced technologies aimed at enhancing productivity and accelerating innovation. These efforts are designed to ensure that Incyte remains competitive in a rapidly evolving biopharmaceutical landscape, where speed, efficiency, and scientific excellence are essential.
As President, Dr. Cagnoni will now contribute more broadly to corporate decision-making, helping guide the company’s strategic planning while ensuring alignment between scientific innovation and business objectives.
Strengthening Clinical Development and Medical Affairs
Dr. Steven Stein has been appointed Executive Vice President, Chief Medical Officer, and Head of Advanced Clinical Development. In this role, Dr. Stein will continue to lead Incyte’s extensive clinical development programs while also overseeing global medical affairs.
Dr. Stein’s responsibilities include managing advanced clinical programs across hematology, oncology, and immunology—three core therapeutic areas for Incyte. His leadership is critical in driving the generation of clinical data, supporting regulatory submissions, and strengthening the company’s scientific credibility within the global medical community.
Having been with Incyte for over a decade, Dr. Stein is widely recognized within the organization for his deep scientific expertise and his commitment to patient-centered development. His contributions have played a key role in the success of several of Incyte’s clinical initiatives, helping bring innovative therapies closer to patients in need.
In his expanded role, Dr. Stein will also oversee international medical affairs, ensuring that Incyte continues to engage effectively with healthcare professionals, researchers, and regulatory bodies worldwide. This function is increasingly important as the company expands its global presence and seeks to demonstrate the value and impact of its therapies across diverse markets.
Enhancing U.S. Commercial Operations
Mohamed Issa, PharmD, has been appointed Executive Vice President and Head of U.S. Commercial Operations. In this position, Issa will continue to lead oncology operations in the United States while taking on additional responsibilities in immunology.
This expanded role reflects a strategic decision by Incyte to integrate its oncology and immunology business lines into a unified U.S. commercial organization. The goal of this integration is to improve coordination, enhance operational efficiency, and ensure consistent execution of product launches across therapeutic areas.
Issa brings extensive experience in commercial strategy, particularly in the successful planning and execution of new product launches. His track record in both oncology and immunology positions him well to lead the integrated commercial organization and drive continued growth in the U.S. market.
By consolidating its commercial operations, Incyte aims to streamline processes, standardize best practices, and maximize the impact of its product portfolio. Issa’s leadership will be critical in maintaining strong commercial performance while supporting the introduction of new therapies.
CEO Perspective on Leadership Changes
Commenting on the appointments, Incyte CEO Bill Meury emphasized the importance of these leadership changes in supporting the company’s future direction.
“These appointments are a testament to the significant contributions Pablo, Steven, and Mohamed have made to Incyte and the continued value they bring to the company,” Meury said. “Furthermore, we are confident that integrating our U.S. sales teams into a single organization will streamline launches and ensure Incyte’s long-term success.”
Meury’s remarks underscore the company’s focus on leveraging internal talent and experience to drive growth, rather than relying solely on external hires. By promoting proven leaders, Incyte aims to maintain continuity while adapting to new opportunities and challenges in the biopharmaceutical industry.
Organizational Transition and Leadership Departure
As part of this broader leadership transition, Matteo Trotta, Executive Vice President and General Manager of Incyte’s U.S. Dermatology business, will be leaving the company following a transition period.
Trotta has played a key role in building and leading Incyte’s dermatology operations in the United States. His departure marks a shift in the company’s organizational structure as it moves toward a more integrated commercial approach.
While the company has not announced a direct replacement for Trotta’s role, the integration of commercial functions under Issa’s leadership suggests a strategic realignment aimed at simplifying operations and improving cross-functional collaboration.
Positioning for Future Growth
These leadership changes come at a pivotal time for Incyte as it continues to expand its pipeline and pursue new opportunities in oncology, immunology, and beyond. The company’s focus on innovation, combined with a strengthened leadership team, positions it well to navigate the complexities of drug development and commercialization.
By aligning its research, clinical, and commercial strategies under experienced leadership, Incyte aims to accelerate the development of new therapies while ensuring successful market adoption. The integration of key functions and the emphasis on operational efficiency reflect a forward-looking approach designed to sustain long-term growth.
Overall, the appointments of Dr. Cagnoni, Dr. Stein, and Mohamed Issa represent a significant step in Incyte’s evolution as a global biopharmaceutical leader. Their combined expertise and leadership will play a central role in advancing the company’s mission to deliver innovative medicines that improve patient outcomes worldwide.
About Incyte® Incyte
is redefining the limits of what is possible in biopharmaceutical innovation. Through deep scientific expertise and a constant focus on patients, we have built a well-established portfolio of first-in-class medicines and a broad portfolio of next-generation medicines in our core business areas: hematology, oncology, and inflammation and autoimmunity.
Except for the historical information presented here, the elements contained in this press release include forecasts, estimates and other forward-looking statements, including any discussion of the strength of Incyte’s corporate leadership and Incyte’s potential for future growth and long-term success.
These forward-looking statements are based on Incyte’s current expectations and are subject to risks and uncertainties that could cause actual results to differ materially from those projected, as described in Incyte’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2025. Incyte disclaims any intention or obligation to update these forward-looking statements.
The text of this press release, being a translation, should not be considered official in any way. The only authoritative version of the press release is the original version in its source language. The translation should always be compared to the source text, which will prevail in case of any discrepancy.
